Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18376117 | 0.76 | RIPK1 (0.45) | SSTR4RIPK1SCN5AALDH1A1KDM4E | |
| SCHEMBL18372677 | 0.75 | SSTR4 (0.43) | SSTR4RIPK1SCN5AALDH1A1SMN1; SMN2 | |
| SCHEMBL30587644 | 0.72 | KMT2A (0.47) | SSTR4RIPK1KDM4EKMT2AUSP7 | |
| SCHEMBL16255866 | 0.70 | SSTR4 (0.50) | SSTR4RIPK1SCN5AALDH1A1SMN1; SMN2 | |
| SCHEMBL2435410 | 0.67 | RAB9A (0.55) | ALDH1A1SMN1; SMN2KDM4EHSD17B10KMT2A | |
| SCHEMBL26634827 | 0.66 | SSTR4 (0.35) | SSTR4KDM4E | |
| SCHEMBL12945003 | 0.65 | SCN5A (0.69) | SSTR4SCN5AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL25371122 | 0.65 | MAPK14 (0.35) | KDM4EHSD17B10 | |
| SCHEMBL24997463 | 0.65 | KMT2A (0.32) | ALDH1A1KMT2APOLBL3MBTL1 | |
| SCHEMBL472513 | 0.62 | KMT2A (0.47) | ALDH1A1SMN1; SMN2KDM4EKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | SSTR4 2731/4885RIPK1 3064/4885SCN5A 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.